Adicet Bio (ACET) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ACET Adicet Bio

Watchlist

1.315
-0.045-3.31%

Trading Oct 31 14:10 ET

108.36MMarket Cap-521P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Reaffirms Their Hold Rating on Adicet Bio (ACET)
TipRanksOct 16 09:07 ET · Ratings
Adicet Bio Advances FDA-Approved Autoimmune Therapy Trials
TipRanksOct 16 07:27 ET
Adicet Bio Announces FDA Clearance of ADI-001 IND Amendment
TipRanksOct 16 07:05 ET
Express News | Adicet Bio Inc: To Report Initial Clinical Data From Phase 1 Study in Multiple Autoimmune Diseases in H1 2025
ReutersOct 16 07:00 ET
Express News | Adicet Bio Inc - Patient Enrollment for Iim and SPS Expected in Q1 2025
ReutersOct 16 07:00 ET
Express News | Adicet Bio Announces FDA Clearance of Ind Amendment to Evaluate Adi-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome
ReutersOct 16 07:00 ET

Comments

Trytosaveabit

Oct 16 06:02

News

$Adicet Bio (ACET.US)$ Reuters· just
Adicet Bio Announces FDA Clearance of Ind Amendment to Evaluate Adi-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Jaguar8

Sep 30 07:48

NEWS

$Adicet Bio (ACET.US)$
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
Adicet Bio (Nasdaq: ACET) has opened enrollment for a Phase 1 clinical trial of ADI-001 in autoimmune diseases. The trial will focus on lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV). Enrollment is currently open for LN patients, with SLE, SSc, and AAV enrollment expected ...

Trytosaveabit

Sep 30 06:05

News

$Adicet Bio (ACET.US)$ Reuters· just
Adicet Bio Inc - FDA Grants Fast Track Designation to Adi-001 for Ln

Trytosaveabit

Sep 19 06:28

Update

$Adicet Bio (ACET.US)$ Adicet Bio Announced ADI-001 Clinical Biomarker Data From The Phase 1 GLEAN Trial Which Further Reinforces The Potential Of ADI-001 As Allogeneic Cell Therapy For Autoimmune Diseases
Benzinga· 4 mins ago
ADI-001 demonstrated robust tissue trafficking resulting in high levels of ADI-001, significant chimeric antigen receptor (CAR) T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue.

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

ACET Adicet Bio

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target